In a significant step forward for patients facing rare and hard-to-treat cancers, iOnctura has announced the expansion of its roginolisib clinical trial program into the United States. This milestone—officially shared on September 9, 2025—marks a major advancement in the company’s multi-indication oncology strategy and brings promising new opportunities for uveal melanoma patients who urgently need more treatment options.
Michelle Tsai, Chief Operating Officer of iOnctura, explained that U.S. clinical trial sites are now active and enrolling eligible participants for OCULE-01, the company’s global study evaluating roginolisib for metastatic uveal melanoma. For many in our community, this expansion represents something we’ve been advocating for: increased access, faster progress, and deeper scientific evaluation of therapies that could finally broaden the treatment landscape.
Roginolisib, a first-in-class PI3Kδ inhibitor, has shown early signals of potential in addressing cancers that have historically been underserved. Tsai emphasized that expanding into the U.S. is not only about scale—it is about impact. The United States hosts one of the world’s most engaged cancer patient communities, where individuals and families are often well-informed about clinical research and motivated to participate. This high level of engagement accelerates the generation of meaningful evidence and builds stronger pathways toward eventual regulatory review.
In addition to OCULE-01, Dr. Jennifer Brown of Dana-Farber Cancer Institute has initiated a separate investigation exploring roginolisib in Chronic Lymphocytic Leukemia (CLL). This multi-indication interest underscores the drug’s potential versatility in tackling complex cancers driven by immune and signaling irregularities.
Tsai also shared a personal reflection—one that resonates deeply with anyone touched by cancer. As a family member of a patient who participated in a clinical trial, she understands firsthand how much hope emerging therapies can bring. For many families, clinical trial access is not just a scientific opportunity—it is an emotional lifeline.
Beyond the scientific and logistical advantages, expanding trials into the U.S. also enhances collaboration with patient advocacy organizations, healthcare institutions, and investors committed to accelerating innovation. This expansion provides opportunities to include more diverse patient populations while increasing awareness of uveal melanoma on a national scale.
For the uveal melanoma community, the arrival of OCULE-01 in the U.S. represents progress, partnership, and renewed optimism. A Cure In Sight will continue to follow this trial closely and keep patients informed as additional updates emerge.